Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

76 results about "Brain dysfunction" patented technology

Gut microflora as biomarkers for the prognosis of cirrhosis and brain dysfunction

A systems biology approach is used to characterize and relate the intestinal (gut) microbiome of a host organism (e.g. a human) to physiological processes within the host. Information regarding the types and relative amounts of gut microflora is correlated with physiological processes indicative of e.g., a patient's risk of developing a disease or condition, likelihood of responding to a particular treatment, for adjusting treatment protocols, etc. The information is also used to identify novel suitable therapeutic targets and / or to develop and monitor the outcome of therapeutic treatments. An exemplary disease / condition is the development of hepatic encephalopathy (HE), particularly in patients with liver cirrhosis.
Owner:VIRGINIA COMMONWEALTH UNIV +1

Il-1 receptor antagonist-coated electrode and uses thereof

InactiveUS20140249396A1Inhibits and reduces and local scarringIncrease stimulationElectroencephalographyHead electrodesDiseaseNervous system
The present invention provides an electrode designed for implantation into the central nervous system (CNS) of a mammal, wherein said electrode is substantially coated with interleukin-1 receptor antagonist (IL-1ra) or a coating composition comprising it, and the IL-1ra actively inhibits scarring on or around the surface of the electrode when implanted into the CNS. The electrode of the invention may be used for brain recording and / or stimulation, and can thus be used for treatment of a brain dysfunction, a brain disease or disorder, or a brain injury, as well as for brain computer interface, brain machine interface, or electrotherapy.
Owner:RAMOT AT TEL AVIV UNIV LTD

Brain dysfunction assessment method, brain dysfunction assessment device, and program thereof

A brain dysfunction assessment device (100) comprises: a body movement indicator (10) which presents a body movement to be performed to a subject with a body movement presentation device (2); a body movement data acquisition unit (20) which acquires the subject's body movement data with a body movement detection sensor (3); a body movement accuracy calculation unit (30) which calculates a positional accuracy and a time sequence accuracy of the subject's body movement from the acquired body movement data; and a cognitive dysfunction assessment unit (40) which assesses the level of cognitive dysfunction of the subject by comparing a value which indicates the accuracy of the subject's body movement that is obtained from the calculated positional accuracy and time sequence accuracy with statistical data which indicates the accuracy of body movement of healthy individuals.
Owner:MAXELL HLDG LTD

Stable preparation of phosphatidylserine and preparation method, application as well as application product of stable preparation

The invention relates to a stable preparation of phosphatidylserine and a preparation method, application as well as an application product of the stable preparation. The preparation method comprises the following step of processing the phosphatidylserine through microencapsulation, micro-pelletization or liposome encapsulation. The stable preparation of the phosphatidylserine can be independently applied as a medicine or can be added into daily foods, drinks and health-care products, also has an important effect on health care of brains while guaranteeing the color and the taste of the daily foods and the drinks of people and is of great benefit to brain disorder such as nutritional supplement of brain development of students, overstrain of nerves of the adults, and memory loss, brain atrophy and senile dementia of the middle aged and elderly people.
Owner:连平劲创生物技术有限公司

IL-1 receptor antagonist-coated electrode and uses thereof

The present invention provides an electrode designed for implantation into the central nervous system (CNS) of a mammal, wherein said electrode is substantially coated with interleukin-1 receptor antagonist (IL-1ra) or a coating composition comprising it, and the IL-1ra actively inhibits scarring on or around the surface of the electrode when implanted into the CNS. The electrode of the invention may be used for brain recording and / or stimulation, and can thus be used for treatment of a brain dysfunction, a brain disease or disorder, or a brain injury, as well as for brain computer interface, brain machine interface, or electrotherapy.
Owner:RAMOT AT TEL AVIV UNIV LTD

Brain dysfunction assessment method, brain dysfunction assessment device, and program thereof

A brain dysfunction assessment device (100) comprises: a body movement indicator (10) which presents a body movement to be performed to a subject with a body movement presentation device (2); a body movement data acquisition unit (20) which acquires the subject's body movement data with a body movement detection sensor (3); a body movement accuracy calculation unit (30) which calculates a positional accuracy and a time sequence accuracy of the subject's body movement from the acquired body movement data; and a cognitive dysfunction assessment unit (40) which assesses the level of cognitive dysfunction of the subject by comparing a value which indicates the accuracy of the subject's body movement that is obtained from the calculated positional accuracy and time sequence accuracy with statistical data which indicates the accuracy of body movement of healthy individuals.
Owner:MAXELL HLDG LTD

Brain dysfunction testing

Systems and methods provided utilize gaze-tracking to measure quantitatively and accurately the ability of an athlete or other subject suspected of a concussion to maintain gaze within a figure-eight pattern during a given period of time. The fixation icon is presented at increasing velocities, with multiple staged velocities constituting the preferred embodiment. Utilizing a figure-eight pattern is preferred. Total tracking error time is tabulated during each velocity stage of the test protocol, and total tracking error time occurring during a given velocity stage is compared to a subject's baseline, e.g., a pre-season Individual Bioperformance Level (IBL) for that velocity stage. Systems and methods disclosed may be used to help prevent debilitating neurological damage in our athlete population, as well as having important military applications related to PTSD, and to other mission-critical performance endeavors.
Owner:MASSENGILL FAMILY TRUST DATED FEBRUARY 22 1996

Hydroquinone Long-Chain Derivative and/or Phenoxy Long-Chain Derivative and Pharmaceutical Comprising Same

The present invention provides compounds represented by formula (1) shown below:(wherein R1, R2, R3, R4, and R5 are each individually selected from among a hydrogen atom, methyl group, acetyl group, hydroxyl group, and alkoxy group; and X represents an alkylene group or alkenylene group); and compounds represented by formula (2) shown below:(wherein R6, R7, R8, R9, and R10 are each individually selected from among a hydrogen atom, alkyl group, acetyl group, hydroxyl group, and alkoxy group; A represents an oxygen atom or NH, and m is 0 or 1; and Y represents an alkylene group or alkenylene group, and Z represents a hydrogen atom or hydroxyl group).The compounds of the present invention are useful for preventing or treating brain dysfunctions, motor dysfunctions, or urinary dysfunctions caused by the degeneration and / or loss of the central nervous system or peripheral nervous system cells.
Owner:UNIVERSITY OF STRASBOURG +1

Water emulsifier composition containing nervonic acid as well as preparation method and application thereof

The invention provides an emulsion composition containing nervonic acid, an emulsifier and water, wherein content of water in the emulsion composition is more than 70% in weight ratio, particle size of a fat globule in the emulsion composition is less than 5Mum, weight ratio of the emulsifier to the nervonic acid is 1:(0.1-6), and the emulsifier comprises one or more than one of the following substances: sucrose fatty acid ester, glyceryl monostearate, glycerol distearate, polyglycerol fatty acid ester, sodium stearoyl lactate and sorbitan fatty acid ester. The invention also provides a preparation method of the emulsion composition and application of the emulsion composition in a health product which is orally taken for supplementing the nervonic acid or unsaturated fatty acid and is used for preventing and treating diseases such as cranial nerve degenerative change, disordered brain function and the like.
Owner:FUZHOU QIANZHENG PHARMA

Asenapine maleate oral instant membrane and making method thereof

InactiveCN104000800ALow costRestrict or completely prevent extractionOrganic active ingredientsNervous disorderDrug contentSchizophrenia
The invention relates to an Asenapine maleate oral instant membrane used for treating adult schizophrenia, chronic severe brain dysfunction and type I bipolar disorder, and a making method thereof. The above dosage form has the advantages of convenient administration, administration without water, rapid dissolving in the oral cavity, restriction or complete prevention of the removal of a medicine by a schizophrenia patient, and improvement of the compliance f the patient. The main drug content of the dosage form made through the making method can reach the unit dosage of Asenapine maleate, and the dosage form has the characteristics of drug loading uniformity, good appearance and good stability. In the production process, the technology is simple, the cost is low, and almost no dust is generated.
Owner:AVENTIS PHARMA HAINAN

Preparation method of Oxiracetam, product of Oxiracetam and use of product

The invention provides a method for preparing Oxiracetam, which comprises the following steps: performing alkaline treatment of 4-hydroxy-2-pyrrolidone under a water-free condition; reacting the treated 4-hydroxy-2-pyrrolidone with 2-chloroacetamide in an organic solvent in the presence of a catalyst; and after the reaction is finished, performing filtration, distillation and recrystallization to obtain the Oxiracetam. In the method, the final product can be obtained by a one-step reaction, the operation is simple and convenient, and large scale production can be realized. The invention also provides the Oxiracetam obtained by the method, which has the characteristics of high yield, high purity and good treatment effect. The invention also provides the use of the Oxiracetam obtained by the method in the preparation of medicaments for treating brain dysfunction, impaired memory and senile dementia.
Owner:TIANJIN INSTITUTE OF PHARMA RESEARCH

Medicinal composition, and its preparing method and use

The present invention discloses a medicine composition. Said medicine composition contains troxerutin obtained by making rutin undergo the process of hydroxyethylation, brain extract extracted from brain tissue of mammal except for human being and ganglioside extracted from brain tissue of mammal except for human being. Said invention also provides the concrete mixing ratio of the above-mentioned three components, and provides its preparation process and application.
Owner:吉林天成制药有限公司

Humanin-like peptide and use thereof

A novel polypeptide having a cell death inhibitory activity and use thereof is provided. The polypeptide and the polynucleotide encoding it can be used as a diagnostic, therapeutic or prophylactic agent for various diseases and disorders. Certain suitable diseases and disorders which may be diagnosed, treated, or prevented with the polypeptide and the polynucleotide encoding it are selected from neurodegenerative diseases, brain dysfunctions, cancers, immunological disease, infections, gastrointestinal diseases, circulatory diseases, and endocrine diseases. The polypeptide and the polynucleotide encoding it can be used as a cell death inhibitor.
Owner:TAKEDA PHARMA CO LTD

Cross coil for deep transcranial magnetic stimulation

The invention provides a crossed transcranial magnetic stimulation coil for improving stimulation depth, the coil is composed of an 8-shaped coil and a Halo coil, the Halo coil surrounds the short axis of the 8-shaped coil, and the upper boundary of the Halo coil is always above the center of the 8-shaped coil. The two parts of the 8-shaped coil are respectively connected with currents in opposite directions to generate a focusing magnetic field, the current direction of the upper boundary of the Halo coil is consistent with the current direction of the tangent position of the 8-shaped coil, and the advantage of stimulation depth is provided. The influence of the Halo coil on the 8-shaped coil is changed by changing the included angle and the distance between the Halo coil and the 8-shaped coil, so that the change relationship between the focusing property and the stimulation depth of the crossed coil is balanced. Based on evaluation standards, compared with an existing deep HFA stimulation coil, the deep HFA stimulation coil has higher stimulation intensity, smaller focusing area and better stimulation depth, and a novel tool with high potential is provided for transcranial magnetic stimulation research and treatment of deep brain dysfunction diseases.
Owner:TIANJIN POLYTECHNIC UNIV

Near-infrared-based multi-band physiological signal feedback system and using method thereof

PendingCN111281399AAchieving self-regulating brain functionImprove spatial resolutionDiagnostic recording/measuringSensorsMulti bandOriginal data
The invention discloses a near-infrared-based multi-band physiological signal feedback system and a using method thereof. The system comprises a physiological signal acquisition module used for acquiring cerebral blood oxygen signals of cerebral cortex of a subject in real time; a data preprocessing module which is used for preprocessing the original data acquired by near infrared spectrum equipment in real time so as to remove noise components in the signals; a multi-band analysis module which is used for extracting multi-band physiological signal intensity index parameters from the preprocessed cerebral blood oxygen signals; a physiological signal feedback module which is used for performing real-time data visualization processing on the intensity index parameters extracted by the multi-band analysis module and feeding back the processed intensity index parameters to the subject; and a display module which is used for displaying the feedback process of the physiological signal feedback module. Based on the near infrared spectrum technology, the physiological activity and nerve activity of the brain in the specific frequency band are adjusted through a five-frequency-band physiological signal feedback method, and the brain dysfunction patient is helped to be trained and rehabilitated better.
Owner:国家康复辅具研究中心

Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases

InactiveCN102309496AReduce infarct sizeAlleviate behavioral disturbances arising from necrosisOrganic active ingredientsNervous disorderDiseaseCoronary heart disease
The invention relates to a pharmaceutical composition for treating cardiovascular and cerebrovascular diseases and an application. The pharmaceutical composition takes ginsenoside Rd and luteolin as main components, is capable of obviously minimizing an infarction area of brain tissue and obviously mitigating the behavior obstacle due to necrotic brain tissue, and achieves the purpose of treating insufficiency of cerebral blood supply, cerebral thrombus, brain embolism, cerebrovascular spasm, brain dysfunction, Alzheimer disease, parkinsons syndrome, cerebral apoplexy, hypertension, hyperlipoidemia, arteriosclerosis, coronary heart disease, angina pectoris and miocardial infarction.
Owner:GUIZHOU XINBANG PHARMACEUTICAL CO LTD

Levodopa preparation and application thereof

InactiveCN105078952AImproving the disturbance of consciousnessOvercome the chillsOrganic active ingredientsNervous disorderReperfusion injuryCerebral resuscitation
The invention relates to levodopa preparation and application thereof. The levodopa preparation comprises, by weight percentage, 70-90% of levodopa and 10-30% of benserazide. The levodopa preparation has the advantages that the levodopa preparation contains the levodopa and the benserazide of fixed content, is applicable to rehabilitation treatment of cerebral dysfunction after cerebral resuscitation, and provides medicine for treating cerebral dysfunction caused by hypoxia-ischemia brain damage after cardio-pulmonary resuscitation; the preparation can be used to prepare medicine for repairing cerebral ischemia-reperfusion injury, medicine for the rehabilitation treatment of cerebral dysfunction after cerebral resuscitation, medicine for treating hypoxia-ischemia brain damage and medicine for replenishing body dopamine; meanwhile, a new purpose of levodopa is provided.
Owner:CHINA REHABILITATION RES CENT

Preparation method of fruit and vegetable fermented low-alcohol beverage

The invention belongs to the fields of food and biotechnology and relates to a preparation method of a fruit and vegetable fermented low-alcohol beverage. Dragon fruits, apples, carrots, pumpkins andskimmed milk powder are subjected to mixed fermentation so as to supplement proteins, folic acid, cellulose, anthocyanin, various vitamins, trace elements and the like required for a human body; and pumpkins, phytosterin and allicin are added so as to reduce the cholesterol value of the fruit and vegetable fermented beverage. The fruit and vegetable beverage prepared by the preparation method provided by the invention can be properly drunk to relieve cardiovascular and cerebrovascular diseases, brain dysfunction and cancer situations. The preparation method provided by the invention has the advantages that multiple strains are subjected to mixed fermentation, and aerobic bacteria and anaerobic bacteria are interacted, so that nutritional components of fruits and vegetables are fully utilized; mixed strains are subjected to lactic acid fermentation by utilizing soluble nutrients of the fruits and the vegetables, and lactic acid bacteria generate multiple vitamins in the fermentation process; after fruit and vegetable juice is fermented, the contents of riboflavin, thiamine, pyridoxine, glutamic acid and the like are increased, so that the nutritional value is improved; and the prepared beverage is unique in flavor, more favorable for human health and capable of improving immunity.
Owner:常州市万昌化工有限公司

Construction and evaluation methods of mouse ischemic stroke model

The invention provides a construction method of a mouse ischemic stroke model. According to the construction method, current stimulation is given to a Common carotid artery (CCA) of a mouse to form a thrombus embolus, the thrombus embolus is activated, the thrombus embolus is made to spontaneously enter the cranium through an Internal carotid artery (ICA), the intracranial Middle artery (MCA) is blocked, and then acute brain blood supply blocking and brain dysfunction are caused. The invention also provides an evaluation method of the mouse ischemic stroke model. The evaluation method comprises the following steps: marking the thrombus embolus formed on the CCA by using a near-infrared fluorescent molecular probe, tracking the position of the thrombus embolus in the mouse cranium by using a small animal living imaging instrument, and evaluating the ICA clogging degree by using fluorescence intensity.
Owner:FUZHOU UNIV

EGCG and gamma-aminobutyric acid composition, and preparation method and applications thereof

The invention provides a health product composition or a pharmaceutical composition containing EGCG and gamma-aminobutyric acid; a drug dosage form includes any pharmaceutically acceptable drug dosage form, and EGCG and gamma-aminobutyric acid are combined according to the weight ratio of (0.2-3):1; furthermore, the invention provides a preparation method of the composition, an application of the composition in preparation of drugs for prevention and treatment of cerebral ischemia, cerebral arteriosclerosis, cerebral embolism and cerebral apoplexy sequela, and an application of the composition in preparation of drugs for prevention and treatment of cerebral nerve degenerative change or cerebral dysfunction disease.
Owner:FUZHOU QIANZHENG PHARMA

Noninvasive optical instrument for cerebrovascular disease treatment

The invention relates to a noninvasive optical instrument for cerebrovascular disease treatment. The instrument is technically characterized by comprising a helmet, a universal lifting frame and a machine shell, a light source is installed inside the helmet, an electric control device is installed inside the machine shell, a display screen is installed on the surface of the machine shell, and thehelmet and the machine shell are installed together through the universal lifting frame; the electric control device comprises a control module and a display module, a driving module, a data storage module and an upper computer module which are connected with the control module; the control module receives an instruction of the upper computer module and drives the light source through the drivingmodule to the turned on or turned off. Light of the specific wavelength is irradiated to a blood vessel or a nerve cell, a cell biochemical reaction can be accelerated, damaged cell tissue is repaired, the blood vessel is dredged, and the instrument can effectively treat cerebral apoplexy, posttraumatic brain dysfunction, child hyperactivity, epilepsy, depression, reading disorder, amnesia, climacteric syndrome, senile dementia and other cerebrovascular nerve diseases.
Owner:INST OF BIOMEDICAL ENG CHINESE ACAD OF MEDICAL SCI

N-substituted alpha-amino acid derivatives and preparation method and application thereof

The invention relates to N-substituted alpha-amino acid derivatives shown in a general formula (I), various salts thereof, hydrates of the salts, monomers of various optical isomers, and mixtures of the various optical isomers, wherein substituents represented by A1 and A2 are groups which are connected to a NCHCOOH structure in the general formula (I) to form alpha-amino, or A1 and A2 are connected to form a five- or six-membered heterocycle or benzohetercyclic ring containing a N heteroatom; A3 represents H or straight-chain or branched alkyl containing 1 to 3 carbon atoms; and A4 and A5 represent H or straight-chain or branched alkyl containing 1 to 3 carbon atoms, or A4 and A5 are connected to form a five- or six-membered heterocycle containing two O heteroatoms. The invention also relates to a preparation method for the N-substituted alpha-amino acid derivatives, a medicinal composition with effects of regenerating and protecting neurone, and application of the N-substituted alpha-amino acid derivatives in preparing medicinal preparations favorable for improving nervous function and treating brain dysfunction, memory decay, dysfunction caused by cerebral circulation insufficiency or neurotransmitter deficiency, and other diseases.
Owner:深圳市天明医药科技开发有限公司

A pharmaceutical composition of cerebroprotein hydrolysate and applications thereof

A pharmaceutical composition of cerebroprotein hydrolysate and applications thereof are disclosed. The composition comprises 15-60 parts by weight of the cerebroprotein hydrolysate, 50-200 parts by weight of ligustrazine hydrochloride, 1-4 parts by weight of sodium DL-beta-(3,4-dihydroxyphenyl)lactate and 100-400 parts by weight of troxerutin. The ligustrazine hydrochloride, the sodium DL-beta-(3,4-dihydroxyphenyl)lactate, the troxerutin and the cerebroprotein hydrolysate are combined for the first time and blended through a proper ratio. The composition has good effects of improving disordered brain functions and preventing cerebral infarction, and can be prepared into any clinically or pharmaceutically acceptable preparation form, preferentially an injection. The composition is definite in effective components and definite in contents, and is mainly used for preparing medicines improving brain functions. A preparing process is simple, convenient and feasible. A preparation is high and stable in quality. The composition is suitable for large-scale industrial production.
Owner:邓学峰

Indole derivatives and drugs containing the same

An indole derivative represented by the following general formula (1):wherein at least one of R1, R2, R3, and R4 represents an alkoxy group containing 1 to 20 carbon atoms, and other groups of the R1, R2, R3, and R4 represent hydrogen, an alkyl group containing 1 to 6 carbon atoms, acetyl group, or hydroxyl group; and either one of X and Y represents —(CH2)nOH wherein n is an integer of 0 to 30, and the other one of the X and Y represents hydrogen atom; or a salt thereof; and a drug and an agent for promoting differentiation of a stem cell containing such indole derivative or its salt as an effective component, wherein the indole derivative (1) has action of inducing differentiation of neural stem cell specifically into a neuron, and this indole derivative is useful as a prophylactic or therapeutic drug for brain dysfunction or neuropathy caused by loss or degeneration of the neuron.
Owner:CENT NAT DE LA RECHERCHE SCI +1

Indole derivatives and drugs containing the same

An indole derivative represented by the following general formula (1): wherein at least one of R1, R2, R3, and R4 represents an alkoxy group containing 1 to 20 carbon atoms, and other groups of the R1, R2, R3, and R4 represent hydrogen, an alkyl group containing 1 to 6 carbon atoms, acetyl group, or hydroxyl group; and either one of X and Y represents —(CH2)n OH wherein n is an integer of 0 to 30, and the other one of the X and Y represents hydrogen atom; or a salt thereof; and a drug and an agent for promoting differentiation of a stem cell containing such indole derivative or its salt as an effective component. The indole derivative (1) of the present invention has action of inducing differentiation of neural stem cell specifically into a neuron, and this indole derivative is useful as a prophylactic or therapeutic drug for brain dysfunction or neuropathy caused by loss or degeneration of the neuron.
Owner:CENT NAT DE LA RECHERCHE SCI +1

1-hydroxy-2-ketopyrrolidine compound and preparation method and application thereof

InactiveCN102491929ACalcium antagonistic activityTreating Brain DisordersOrganic active ingredientsNervous disorderOrtho positionStructural formula
The invention discloses a 1-hydroxy-2-ketopyrrolidine compound with a novel structure, i.e., 1-hydroxy-4-substituted phenyl-5-substited phenmethyl-2-ketopyrrolidine. The general formula of the compound is shown in a structural formula I, wherein X and Y are selected from hydrogen, ortho-position, meta-position and contraposition mono-substituted or multi-substituted fluorine and / or chlorine and / or bromine, and ortho-position, meta-position and contraposition mono-substituted or multi-substituted methoxyl and / or ethyoxyl and / or methyl; and X and Y are the same or different. The compound provided by the invention has calcium antagonistic activity, particularly has high selectivity calcium antagonistic activity to nerve cells, can be applied to preparation of a medicament with a calcium antagonistic action, and can be expected to be taken as a brain protecting agent for treating brain dysfunction, senile dementia, presenile dementia, vascular dementia or low learning and memory capabilities; and the preparation method provided by the invention has the advantages of quick reaction, easiness, easiness for operating, suitability for large-scale preparation and easiness for realizing industrial production. The structural I is shown in the description.
Owner:THE KEY LAB OF CHEM FOR NATURAL PROD OF GUIZHOU PROVINCE & CHINESE ACADEMY OF SCI

Composition for Preventing or Treating Oxidative Brain Damage and Brain Dysfunction, and Production Method for Same

ActiveUS20150328271A1Outstanding preventive effectOutstanding therapeutic effectBiocideNervous disorderSalvia miltiorrhizaInjury brain
Provided is a composition for preventing or treating oxidative brain injury and brain dysfunction including an extract of Astragali Radix and Salvia Miltiorrhizae Radix as an active ingredient, the composition having a highly outstanding preventive or therapeutic effect in animal models simulating brain-tissue damage and brain dysfunction induced by acute and long-term excessive stress generated in actual clinical practice, which is effectively usable as a therapeutic agent thereof.
Owner:DAEJEON UNIV IND UNIV COOPERATION FOUND
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products